The Nephstrom project and the promise of Orbsen’s stromal cell therapy are up for discussion when RegMedNet interviews Remedi Chair (and Orbsen Director), Professor Timothy O’Brien.

“Funded by a €6-million grant from the European Union Horizon 2020 programme and including many partners, the project is now setting up a stem cell factory with the NHS in Liverpool (UK) and will be conducting a clinical trial of its allogeneic bone marrow stromal cell product (ORBCEL-M) in 48 Type 2 diabetes patients at high risk of developing diabetes-related kidney problems, in the hope of reducing kidney inflammation and improving kidney function.”

Read the story, including the Q&A with Prof O’Brien at RegMedNet.